- B.S. in Biomedical Science, Midwestern University-Glendale
- Pharm.D., Wingate University School of Pharmacy
- Pharmacy Practice Residency, St. Vincent’s Medical Center, Jacksonville, FL
- Infectious Diseases Specialty Residency, University of Pittsburgh Medical Center
- Infectious Diseases Pharmacotherapy Research Fellowship, Wayne State University, Detroit
Anthony M. Casapao received his Doctor of Pharmacy degree from Wingate University in Wingate, North Carolina. He then pursued post-graduate training at St. Vincent’s Medical Center in Jacksonville, Florida, by completing an American Society of Health-System Pharmacists, or ASHP, -accredited pharmacy practice residency. Casapao continued his post-graduate training at University of Pittsburgh Medical Center in Pennsylvania, completing an ASHP-accredited specialty practice residency in infectious diseases. Upon completion of his residency, he maintained his interest in infectious diseases and pursued an American College of Clinical Pharmacy peer reviewed pharmacotherapy fellowship in infectious diseases and health outcomes. After achieving five years post-graduate training, Casapao served as an assistant professor in the department of pharmacy practice at Husson University School of Pharmacy in Bangor, Maine. Casapao joined the University of Florida in October 2017, as a clinical assistant professor in the department of pharmacotherapy and translational research.
- American Association of Colleges of Pharmacy
- American Society of Microbiology
- Florida Society of Health-System Pharmacists
- Infectious Diseases Society of America
- Making a Difference in Infectious Disease
- Society of Infectious Diseases Pharmacists
Casapao’s research interest focuses on pharmacoepidemiology, antimicrobial resistance and health outcomes. Specifically, he is interested in the clinical implications in anti-infective resistance, using stochastic modeling to determine appropriate antibiotic selection and infectious diseases surveillance and epidemiology.
Casapao AM, Jacobs DM, Bowers DR, Beyda NE, Dilworth TJ; REACH-ID Study Group. Early administration of adjuvant β-lactam therapy in combination with vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a retrospective, multicenter analysis. Pharmacotherapy. 2017 Sep 26. [Epub ahead of print].
Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, Klinker KP, Davis SL, Rybak MJ. A Multicenter Observational Study of Ceftaroline Fosamil for Methicillin- Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother. 2017 Jan;61(2).
Claeys KC, Zasowski EJ, Casapao AM, Lagnf AM, Nagel JL, Nguyen CT, Hallesy J, Compton MT, Kaye KS, Levine DP, Davis SL, Rybak MJ. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5841-8.
Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ. Association Between Vancomycin Day 1 Exposure Profile and Outcomes Among Patients with Methicillin- Resistant Staphylococcus aureus Infective Endocarditis. Antimicrob Agents Chemother. 2015 Jun;59(6): 2978-85.
Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, Levine DP, Rybak MJ. Evaluation of Vancomycin Population Analysis Profile Susceptibility as a Predictor of Patient Outcomes with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. Antimicrob Agents Chemother. 2014 Aug;58(8):4636-41.
Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. A Large Multicenter Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy for Severe Infections. Antimicrob Agents Chemother. 2014 May;58(5):2541-6.
Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections. Antimicrob Agents Chemother. 2013 Sep;57(9):4190-6.
Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, LaPlante KL, Potoski BA, Rybak MJ. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infection. Antimicrob Agents Chemother. 2013 Sep;57(9):4252-9.